Nanoprobe technology for detection and analysis of RNA at single-cell level in liquid biopsy for cancer diagnosis and precision medicine
The technology
We've created bespoke nanoprobe technology designed for the detection and analysis of ribonucleic acid (RNA) at the single-cell level, with application in the early detection, prognosis, efficacy assessment, and prediction of aggressive primary cancers.
Our liquid biopsy technology is a disruptive diagnostic that bridges a critical gap in technologies for the detection of molecular markers with minimal liquid biological samples. Our technology relies on bespoke RNA nanoprobes based on a novel type of nanoprobe to detect RNA biomarkers at the single-cell level through fluorescence detection systems such as flow cytometry and fluorescence microscopy. This allows analysis of the expression level of RNA biomarkers at the single-cell level.
We plan to construct novel prototype fluorescence instrumentation to enable high throughput rapid quantitative RNA analysis at the single-cell level in conjunction with our RNA nanoprobes.
Our nanoprobes have been shown to identify cancer molecular biomarkers in circulating tumour cells in the blood
Combining our nanoprobe assay with quantitative analysis, our technology provides the opportunity for a game-changing in vitro liquid biopsy diagnostic.